Guardian Pharmacy Q3 revenue falls 2% but beats estimates on resident growth
GRDN•Guardian Pharmacy’s Q3 revenue fell 2% year over year to $371.07 million but beat estimates of $365.76 million, while adjusted EPS rose to $0.33. The company raised its FY 2026 revenue guidance to $1.44 billion-$1.46 billion and adjusted EBITDA guidance to $136 million-$138 million.
1. Quarterly results
Guardian Pharmacy reported Q3 revenue of $371.07 million, down 2% year over year and above the $365.76 million analyst estimate. Adjusted EPS rose to $0.33. The company said the revenue decline reflected pricing decreases from the Inflation Reduction Act, while the number of residents served grew 7% year over year.
2. Raised outlook
The company raised its FY 2026 revenue guidance to $1.44 billion-$1.46 billion from $1.43 billion-$1.45 billion. It lifted its adjusted EBITDA outlook to $136 million-$138 million from $129 million-$131 million, citing favorable industry fundamentals and substantial runway for growth.
3. Margin improvement
CEO Fred Burke attributed margin gains to the scalability of the operating model and leverage across a growing resident base.
